ROIV vs RXRX Stock Comparison
Compare ROIV and RXRX across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between ROIV and RXRX?
ROIV leads the current stock comparison as Roivant Sciences Ltd., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Roivant Sciences Ltd. vs Recursion Pharmaceuticals, Inc.
ROIV leads
ROIV leads by 19 AIQ points, primarily on Momentum and Quality, and the lead has widened from 13 points over 30 sessions. Wall Street currently favors RXRX on target upside.
Stable: 2 of 6 evidence groups support ROIV, its lead is widening, and its signal state is cleanly positive.
Roivant Sciences Ltd.
Recursion Pharmaceuticals, Inc.
The Algovestiq AIQ Score currently favors ROIV over RXRX, 56 versus 37 as of Sep 11, 2026. ROIV's advantage is driven primarily by stronger momentum and quality. ROIV also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors RXRX. 2 of 6 covered evidence groups favor ROIV today, and the comparison is rated Stable on stability: only 2 of 6 covered evidence groups agree. ROIV lead: Strengthening — the AIQ differential moved from 13 to 19 points over 30 sessions.
Compare Roivant Sciences Ltd. and Recursion Pharmaceuticals, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare ROIV and RXRX against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum76 vs 38ROIV +38
- Quality60 vs 29ROIV +31
- Risk Resilience61 vs 58Even
- Value34 vs 34Even
2 of 6 evidence groups favor ROIV. ROIV’s edge is concentrated in momentum and quality.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum -1
No new signals fired.
Largest factor move: Momentum +2
No new signals fired.
ROIV's lead narrowed by 1 AIQ points in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — ROIV and RXRX both carry a full feed there.
The central trade-off
ROIV (Roivant Sciences Ltd.): the stronger current systematic profile, led by momentum and quality.
RXRX (Recursion Pharmaceuticals, Inc.): the counter-case, on fundamentals, analyst expectations — but at materially higher volatility, 82.8% against 75.4%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
ROIVROIV on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
RXRXRXRX on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
ROIVROIV on the Momentum factor, by 38 points.
Lower downside
ROIVROIV carries the lower 1-month annualized volatility.
Analyst upside
RXRXRXRX on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors ROIV, analyst targets favor RXRX. That disagreement is the most useful thing on this page.
| Measure | ROIV | RXRX | Note |
|---|---|---|---|
| Implied upside to target | -2% | +68.8% | RXRX has more room |
| Target dispersion | +15% | +3.7% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 5 | 1 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
2 of 6 covered evidence groups favor ROIV. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | ROIV | 56 vs 37 |
| Fundamentals | RXRXon balance | revenue growth -42.8% vs 18.5%; EPS growth -160.5% vs -13.6%; TTM ROE -6.1% vs -50.4%; gross margin 81.2% vs -46.7%; operating margin -181.4% vs -9.9% — RXRX takes 3 of 5 decided legs, not all of them |
| Valuation | Even | Value 34 vs 34 |
| Technicals | ROIV | Price vs 50-day 14.4% vs -3.2%; vs 200-day 42.1% vs -13.1% |
| Risk Resilience | Even | Risk Resilience 61 vs 58 |
| Analyst expectations | RXRX | Target upside -2% vs 68.8% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of ROIV and RXRX and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 19 points. (supports the conclusion holding)
- Only 2 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been widening. (supports the conclusion holding)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ROIV.
How the comparison changed
119 daily snapshots · May 4 – Sep 10ROIV lead: Strengthening — the AIQ differential moved from 13 to 19 points over 30 sessions.
- Today
- ROIV +19
- 56 vs 37
- 7 sessions ago
- ROIV +5
- 49 vs 44
- 30 sessions ago
- ROIV +13
- 58 vs 45
- 90 sessions ago
- ROIV +13
- 59 vs 46
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
6 bullish / 0 bearish / 1 neutral
- Golden Cross Active — bullish, trend, long horizon (23.86%)
- Keltner Channel Breakout — bullish, volatility, short horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
0 bullish / 3 bearish / 1 neutral
- Death Cross Active — bearish, trend, long horizon (9.97%)
- Downtrend Structure Active — bearish, trend, long horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (6.16%)
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price and the AIQ Score both moved down over the latest session (price -0.29%, AIQ -1 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.27%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1RXRX closes the Momentum gap — currently 38 points behind, the largest single contributor to ROIV's edge.
- 2RXRX's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3ROIV's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
RXRX leads on balance| Metric | ROIV | RXRX |
|---|---|---|
| Revenue growth (YoY) | -42.8% | 18.5% |
| EPS growth (YoY) | -160.5% | -13.6% |
| Gross margin | 81.2% | -46.7% |
| Operating margin | -181.4% | -9.9% |
| Return on equity (TTM) | -6.1% | -50.4% |
| Debt to equity | 0.03 | 0.07 |
Performance
ROIV leads 6 of 6 windows| Metric | ROIV | RXRX |
|---|---|---|
| 1 week (5 sessions) | 19.8% | -6.5% |
| 1 month (20 sessions) | 13.2% | -4% |
| 3 months (63 sessions) | 44.1% | 3.9% |
| 6 months (126 sessions) | 38.4% | -8.4% |
| Year to date | 88.7% | -22.7% |
| 1 year (252 sessions) | 217.1% | -31.6% |
Technicals
ROIV has the stronger structure| Metric | ROIV | RXRX |
|---|---|---|
| RSI (14) | 64.9 | 45.1 |
| ADX (14) | 20.2 | 12.8 |
| Price vs 50-day | 14.4% | -3.2% |
| Price vs 200-day | 42.1% | -13.1% |
| Volatility (1M, annualized) | 75.4% | 82.8% |
Risk
Split| Metric | ROIV | RXRX |
|---|---|---|
| Beta | 1.01 | 2.88 |
| Sharpe ratio | 2.53 | -0.26 |
| Sortino ratio | 6 | -0.5 |
| Max drawdown | -12.8% | -58.2% |
| Current drawdown | -2.1% | -53.5% |
| Annualized volatility | 46.6% | 71.8% |
| Value at risk (95%) | -2.9% | -6.6% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, ROIV or RXRX?
On the Algovestiq AIQ Score, ROIV is the stronger of the two as of Sep 11, 2026, scoring 56 against RXRX's 37. The edge comes from momentum and quality. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is ROIV or RXRX the better buy right now?
ROIV carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Stable — 2 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor ROIV over RXRX?
The composite weights Quality, Value, Momentum and Risk Resilience. ROIV leads Momentum by 38 points; ROIV leads Quality by 31 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, ROIV or RXRX?
Analyst price targets imply -2% upside for ROIV and +68.8% for RXRX, so the Street currently favors RXRX. That points the opposite way to the AIQ Score, which favors ROIV. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, ROIV or RXRX?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, ROIV or RXRX?
RXRX on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, ROIV or RXRX?
ROIV on the Momentum factor, by 38 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, ROIV or RXRX?
ROIV is the more resilient of the two, so the other name carries the higher downside risk. ROIV carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is ROIV more profitable than RXRX?
The profitability evidence is mixed: gross margin 81.2% vs -46.7%; operating margin -181.4% vs -9.9%; ttm roe -6.1% vs -50.4%. ROIV leads on two measures and RXRX on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is ROIV's lead over RXRX getting stronger or weaker?
ROIV lead: Strengthening — the AIQ differential moved from 13 to 19 points over 30 sessions. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has not changed hands in that window.
What would change the ROIV vs RXRX verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: RXRX closes the Momentum gap — currently 38 points behind, the largest single contributor to ROIV's edge; RXRX's Death Cross Active resolves — a bearish trend rule currently active against it; ROIV's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about ROIV and RXRX?
ROIV: 6 bullish / 0 bearish / 1 neutral. RXRX: 0 bullish / 3 bearish / 1 neutral. The most decision-relevant rule on ROIV is Golden Cross Active (bullish, long horizon). On RXRX it is Death Cross Active (bearish, long horizon).
Compare ROIV and RXRX with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.